Juma F D, Rogers H J, Trounce J R
Br J Clin Pharmacol. 1979 Sep;8(3):209-17. doi: 10.1111/j.1365-2125.1979.tb01004.x.
Plasma cyclophosphamide levels were estimated by gas-chromatography in seven patients following intravenous and oral cyclophosphamide administration. Plasma alkylating activity was determined by the nitrobenzyl pyridine (NBP) reaction. The plasma after intravenous administration ranged from 5.97 to 12.37 h but after oral administration was shorter, 1.32-6.8 h. The mean total body clearance was 66.6 ml kg h after intravenous dosing and 93.1 ml kg h following oral dosing. β was 0.71 (0.10 s.d.) 1 kg suggesting that cyclophosphamide is distributed largely in body water. The mean hepatic extraction ratio was 0.25, indicating a modest first pass metabolism. The metabolic clearance was 3.72 1 kg and the intrinsic hepatic clearance 5.17 1 kg. The mean renal clearance was 4.8 ml kg h with 6.5% of the administered dose excreted unchanged in the urine suggesting tubular reabsorption of cyclophosphamide. The mean of plasma alkylating activity was 8.82 h, there being no significant difference following oral and intravenous administration. On average, 3.5 times the alkylating activity was produced by an oral dose of cyclophosphamide as compared to an intravenous dose. It is possible that this may reflect production of a different pattern of alkylating metabolites following cyclophosphamide administration by different routes. The clinical significance of these observations is unknown.
通过气相色谱法对7例静脉注射和口服环磷酰胺后的患者血浆中环磷酰胺水平进行了估算。通过硝基苄基吡啶(NBP)反应测定血浆烷基化活性。静脉给药后血浆半衰期为5.97至12.37小时,但口服给药后较短,为1.32 - 6.8小时。静脉给药后平均全身清除率为66.6 ml/kg/h,口服给药后为93.1 ml/kg/h。β为0.71(标准差0.10)1/kg,表明环磷酰胺主要分布于身体水分中。平均肝提取率为0.25,表明存在适度的首过代谢。代谢清除率为3.72 1/kg,肝固有清除率为5.17 1/kg。平均肾清除率为4.8 ml/kg/h,给药剂量的6.5%以原形经尿液排出,提示环磷酰胺存在肾小管重吸收。血浆烷基化活性的平均半衰期为8.82小时,口服和静脉给药后无显著差异。平均而言,口服环磷酰胺产生的烷基化活性是静脉给药剂量的3.5倍。这可能反映了不同给药途径后环磷酰胺产生的烷基化代谢物模式不同。这些观察结果的临床意义尚不清楚。